Scarica l'app Stockscreener
15.99
0.68%
-0.11
Dopo l'orario di chiusura:
15.99
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$16.10
Aprire:
$16.3
Volume 24 ore:
719.75K
Relative Volume:
0.57
Capitalizzazione di mercato:
$1.32B
Reddito:
$46.02M
Utile/perdita netta:
$-70.80M
Rapporto P/E:
-8.7857
EPS:
-1.82
Flusso di cassa netto:
$-1.61M
1 W Prestazione:
-9.86%
1M Prestazione:
+33.36%
6M Prestazione:
+80.47%
1 anno Prestazione:
+101.39%
Intervallo 1D:
$15.97
$16.54
Intervallo di 1 settimana:
$15.97
$19.11
Portata 52W:
$3.91
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Nome
Eyepoint Inc
Settore
Industria
Telefono
617-926-5000
Indirizzo
480 PLEASANT STREET, WATERTOWN, MA
Confronta EYPT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
15.99 | 1.33B | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-07 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-22 | Iniziato | JP Morgan | Overweight |
| 2023-11-02 | Iniziato | Mizuho | Buy |
| 2023-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2022-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2021-03-01 | Iniziato | Cowen | Outperform |
| 2021-01-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Ripresa | Laidlaw | Buy |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
Mostra tutto
Eyepoint Inc Borsa (EYPT) Ultime notizie
Certain Pre-Funded Warrants of EyePoint, Inc. are subject to a Lock-Up Agreement Ending on 14-DEC-2025. - marketscreener.com
Cormorant Asset Management Reduces Stake in EyePoint Pharmaceuti - GuruFocus
After Leaping 38% EyePoint, Inc. (NASDAQ:EYPT) Shares Are Not Flying Under The Radar - simplywall.st
Update Report: Is EyePoint Pharmaceuticals Inc stock positioned for long term growth2025 Biggest Moves & High Accuracy Swing Trade Signals - moha.gov.vn
Stempoint Capital LP Acquires New Position in Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
EyePoint stock maintains Outperform rating at Mizuho amid competitor moves By Investing.com - Investing.com Australia
EyePoint stock maintains Outperform rating at Mizuho amid competitor moves - Investing.com
EyePoint Pharmaceuticals (EYPT) Maintains Positive Outlook Amid Competitive Dynamics - GuruFocus
Walleye Capital LLC Has $1.88 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
EyePoint (EYPT) Is Up 25.0% After DURAVYU Phase 3 Safety Green Light And $200M ATM Offering - simplywall.st
Federated Hermes Inc. Has $43.28 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Understanding Momentum Shifts in (EYPT) - news.stocktradersdaily.com
EyePoint Pharmaceuticals changes name to EyePoint Inc - marketscreener.com
EyePoint Pharmaceuticals changes name to EyePoint, Inc., retains EYPT ticker - Investing.com
EyePoint Pharmaceuticals Announces Official Name Change - TipRanks
EyePoint Pharmaceuticals changes name to EyePoint, Inc., retains EYPT ticker By Investing.com - Investing.com India
EyePoint Pharmaceuticals announces official name change - MSN
EyePoint Pharmaceuticals Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Sets New 12-Month HighHere's What Happened - MarketBeat
How EyePoint Pharmaceuticals Inc. (PV3B) stock responds to job market shiftsMarket Growth Review & Community Consensus Trade Signals - Newser
Can EyePoint Pharmaceuticals Inc. (PV3B) stock deliver strong annual returnsWeekly Trading Summary & Real-Time Volume Trigger Notifications - Newser
How buyback programs support EyePoint Pharmaceuticals Inc. (PV3B) stockMarket Risk Report & Smart Investment Allocation Tips - Newser
Will EyePoint Pharmaceuticals Inc. stock outperform value stocksQuarterly Portfolio Review & AI Powered Trade Plan Recommendations - Newser
Eyepoint Pharmaceuticals stock hits 52-week high at 15.0 USD - Investing.com
Eyepoint Pharmaceuticals stock hits 52-week high at 15.0 USD By Investing.com - Investing.com South Africa
Will EyePoint Pharmaceuticals Inc. (PV3B) stock outperform energy sector in 2025CPI Data & Weekly Return Optimization Plans - Newser
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Is EyePoint Pharmaceuticals Inc. (PV3B) stock positioned for secular growthWeekly Earnings Recap & Fast Entry Momentum Alerts - Newser
EyePoint Pharmaceuticals: Promising Outlook for Duravyu in Wet AMD Treatment and Strategic Growth Potential - TipRanks
EyePoint Pharmaceuticals Director Sells Shares - TradingView
XTX Topco Ltd Acquires 94,210 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
What drives EyePoint Pharmaceuticals Inc stock priceEvening Star Patterns & Exceptional Return Capital - earlytimes.in
Investors Appear Satisfied With EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Prospects As Shares Rocket 26% - 富途牛牛
EyePoint Pharmaceuticals (EYPT) Is Up 8.4% After Positive Phase 3 Safety Review for DURAVYU - Sahm
Officer/Dir Lurker Files To Sell 500 Of EyePoint Pharmaceuticals Inc [EYPT] - TradingView
What analysts say about EyePoint Pharmaceuticals Inc PV3B stockHigh Dividend Yield Stocks & Access Free Risk Analysis Before You Invest - earlytimes.in
Avoiding Lag: Real-Time Signals in (EYPT) Movement - news.stocktradersdaily.com
EyePoint Pharmaceuticals (EYPT): A Fresh Valuation Look Following Key DURAVYU Phase 3 Safety Review Completion - Sahm
Will EyePoint Pharmaceuticals Inc. stock see PE expansionJuly 2025 Patterns & Stepwise Entry and Exit Trade Signals - BỘ NỘI VỤ
Franklin Resources Inc. Buys 151,262 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Eyepoint Pharmaceuticals stock hits 52-week high at $14.94 By Investing.com - Investing.com Nigeria
Eyepoint Pharmaceuticals stock hits 52-week high at $14.94 - Investing.com
EyePoint receives second consecutive positive recommendation from DSMC - Modern Retina
Why Institutions Believe Infibeam Avenues Limited Is Undervalued TodayStock Watchlist Updates & Collaborate and Win Together - earlytimes.in
EyePoint Pharmaceuticals (EYPT) Clears Phase 3 Safety Hurdle for DURAVYU—Is a New Wet AMD Era Ahead? - Sahm
Can EyePoint Pharmaceuticals Inc. (PV3B) stock sustain double digit ROETrade Risk Report & Detailed Earnings Play Alerts - newser.com
EyePoint Pharmaceuticals stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Australia
Eyepoint Inc Azioni (EYPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):